• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
CommentaryVaccines

Gutting this federal program could undermine Americans’ confidence in a COVID vaccine

By
Leah Durant
Leah Durant
Down Arrow Button Icon
By
Leah Durant
Leah Durant
Down Arrow Button Icon
September 6, 2020, 11:00 AM ET
Gutting this federal program could undermine American confidence in a COVID vaccine
Administration of the flu vaccine. Gutting a federal program that insures Americans against vaccine injuries will damage Americans' trust in a COVID vaccine, writes Leah Durant. Antonio Perez—Chicago Tribune/Tribune News Service via Getty ImagesAntonio Perez—Chicago Tribune/Tribune News Service/Getty Images

We may have a coronavirus vaccine as soon as this fall. But millions of Americans already say they won’t get it. More than six in 10 adults think any first-generation COVID-19 vaccine will pose either a “large” or “moderate” risk to their health, according to a new Ipsos survey.

That’s concerning, given that decades of scientific evidence prove just how safe vaccines are. A vaccine offers the best chance of ending the pandemic. Boosting public confidence in them is crucial.

Unfortunately, federal officials are doing just the opposite. Late last month, the Department of Health and Human Services issued a draft rule that would gut the National Vaccine Injury Compensation Program, a little-known initiative that provides payment to the very few people harmed by vaccines.

Scaling back the program would hurt not just those who have been injured but the many more people who count on vaccines to protect them from dangerous diseases.

Few medical advances have saved more lives than vaccines. For example, measles infected nearly 4 million Americans—and killed hundreds—every year before a vaccine was created in the 1960s. Today, the CDC says measles has been effectively “eliminated from the United States” thanks to the MMR shot. The flu vaccine, meanwhile, prevents millions of people from contracting influenza annually and saves thousands of lives.

Just like any other medicine, vaccines can cause side effects. Usually, they’re mild. But on rare occasions, more serious side effects—including life-threatening reactions, diseases, or debilitating shoulder injuries from the vaccine’s contents and improper injections—can occur.

Until the late 1980s, these injuries sparked lawsuits. Juries awarded such large payouts to several parents whose infants were injured by the pertussis vaccine that drug companies ceased production for fear of further litigation.

Policymakers rightly feared that lawsuits like these would chill vaccine development—and lead to more sickness and death in the long run. So Congress passed a law indemnifying drug companies and health care providers from vaccine-related liabilities.

At the same time, lawmakers created the National Vaccine Injury Compensation Program, which reimburses people harmed by vaccines for their medical bills, lost wages, and additional pain and suffering. Since 1988, the program has paid out more than $4.3 billion to about 7,400 qualifying victims.

The standards for the program are exacting. More than 60% of adjudicated petitions have been rejected by the court that oversees the program. For every million doses of vaccine distributed, one person receives compensation.

The program has been enormously successful. It enables drug companies to confidently invest in vaccine development. It encourages doctors and nurses to inoculate their patients without fear of a malpractice suit. And it reassures patients they’ll be compensated (my law firm works on such cases), on the off chance they do experience a serious reaction.

The draft rule undermines all three of those objectives. It does so by attempting to delete an injury from the list of those eligible for compensation. That injury just so happens to be the most common: “shoulder injury related to vaccine administration,” or SIRVA.

More than half of all claims that come before the program are for SIRVA. These injuries—which include rotator cuff tears, tendonitis, bursitis, and frozen shoulder—occur when doctors or nurses inject patients too high in the shoulder or choose an inappropriate needle length, and the vaccine causes an inflammatory reaction resulting in injury. People afflicted with SIRVA can require painful surgeries to recover and may lose use of their arms for months or years.

There’s no new science to justify removing SIRVA from the list of covered injuries. But federal officials are struggling with a backlog of claims against the program. Scrapping the most common source of claims would certainly help clear that backlog—at the expense of people who are suffering.

The move could also hamstring public health officials’ efforts to roll out widespread immunization programs against the coronavirus or any other vaccine-preventable disease. If people fear they won’t have recourse if they’re harmed by a vaccine, they won’t get inoculated.

At a time when more than 150,000 Americans have died from COVID-19, the last thing the government should do is give people an excuse to forgo vaccination.

Preserving the National Vaccine Injury Compensation Program is one of the best ways to ensure widespread participation by doctors, nurses, and patients in vaccination campaigns. Federal officials must rethink their proposed changes to the program.

Leah Durant is a Washington, D.C.-based vaccine injury attorney.

About the Author
By Leah Durant
See full bioRight Arrow Button Icon

Latest in Commentary

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Commentary

Commentaryphilanthropy
Asia’s family offices and corporations must step up to replace a cash-strapped UN and fill the SDG funding gap
By Naina Subberwal BatraMarch 8, 2026
23 hours ago
herrick
CommentaryWealth
I’ve been advising wealthy family offices on real estate for decades. This market requires another look at your 100-year plan
By Belinda G. SchwartzMarch 7, 2026
2 days ago
adams
CommentaryVaccines
Trump’s former Surgeon General: voters widely support vaccine access and want Washington to focus elsewhere
By Jerome AdamsMarch 7, 2026
2 days ago
schmidt
CommentaryData centers
Eric Schmidt: big tech should power its own AI ambitions 
By Eric SchmidtMarch 6, 2026
3 days ago
sarandos
CommentaryMedia
What Netflix’s acquisition of Ben Affleck’s AI filmmaking company really shows
By Lin CherryMarch 6, 2026
3 days ago
iran
CommentaryOil
Bypassing Hormuz: how technology, not territory, will win the new energy war
By Siddharth MisraMarch 6, 2026
3 days ago

Most Popular

placeholder alt text
Success
Gen Z graduates who majored in ‘AI-proof’ careers like pharmacy, biology, and education are making less than $50,000 after graduation
By Emma BurleighMarch 6, 2026
3 days ago
placeholder alt text
Success
This AI founder who quit her 9-to-5 law job has a warning for anyone dreaming of doing the same: 'I'm working harder now than I ever did'
By Emma BurleighMarch 8, 2026
1 day ago
placeholder alt text
AI
Anthropic just mapped out which jobs AI could potentially replace. A 'Great Recession for white-collar workers' is absolutely possible
By Jake AngeloMarch 6, 2026
3 days ago
placeholder alt text
Economy
Trump’s $175 billion illegal tariff revenue is now accruing interest, and refund delays could be costing American taxpayers $700 million a month
By Sasha RogelbergMarch 4, 2026
5 days ago
placeholder alt text
Energy
Forget the U.S. Navy. The best protection for ships traveling through the Strait of Hormuz may be claiming to be a 'Chinese' or 'Muslim' vessel
By Jason MaMarch 7, 2026
2 days ago
placeholder alt text
Energy
'Nightmare scenario' looms as global markets head for the biggest oil output disruption in history, top energy guru warns
By Jason MaMarch 8, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.